Share this article
Share this article
SEONGNAM, South Korea, April 6, 2021 /PRNewswire/ Bridge Biotherapeutics Inc.(288330 KQ), a clinical-stage biotech company headquartered in Seongnam, Republic of Korea, announced that the company has initiated the Phase 1/2 clinical trial assessing safety, tolerability, and anti-tumor activity of BBT-176 in non-small cell lung cancer (NSCLC) patients who acquired osimertinib-resistant EGFR triple mutations.
BBT-176, a novel epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is designed to inhibit the signaling pathway of EGFR with C797S mutations, which arises due to osimertinib (Tagrisso)-resistant mutations in NSCLC. The mutation results in a cysteine to serine change on amino acid 797 within the kinase domain sequence of the EGFR. From the pre-clinical studies, BBT-176 exhibited anti-tumor efficacy in mouse xenograft models and anti-brain metastases in patient-derived orthotopic xenograft models.
OSE Immunotherapeutics Announces First Peer-Reviewed Publication in Science Advances on OSE-230, its Novel Monoclonal Antibody Agonist Therapy Triggering Resolution of Chronic Inflammation
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-176 in EGFR-Mutant NSCLC with C797S
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Evidence-based clinical practice guideline aims to optimize PD-L1 lung tumor testing
The College of American Pathologists (CAP), in collaboration with five other societies, developed a draft evidence-based clinical practice guideline that aims to optimize PD-L1 testing for patients with non-small cell lung cancer (NSCLC) who are being considered for immunooncology therapy.
The guideline, PD-L1 Testing of Patients With Lung Cancer for Immunooncology Therapies, includes a draft summary of six recommendations, which is now available for an open comment period from March 31 to April 23, 2021.
All stakeholders-;including pathologists, oncologists, hospital or laboratory managers, and patient advocacy group representatives-;are encouraged to review and submit feedback on these draft recommendations.